Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function

Human Cell

Volumn 21, Issue 3, 2008, Pages 64-69

  Hashimoto, Hisashi ^a,c   Kojima, Atsumi ^c   Sudo, Tamotsu ^a,d   Ohki, Noriyoshi ^a   Yamaguchi, Satoshi ^a   Mikami, Yoshiki ^b   Ito, Masaharu ^c   Nishimura, Ryuichiro ^a,b  

^a HYOGO CANCER CENTER   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NONE   (Japan)

Author keywords

Cell line; Human; p53; Papillary carcinoma; Uterine neoplasm

Indexed keywords

PROTEIN P53;

AGED; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CYTOLOGY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; MOUSE; MUTATION; NONHUMAN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; UTERUS PAPILLARY SEROUS CARCINOMA;

AGED; ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; HUMANS; KARYOTYPING; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 48449087476     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1111/j.1749-0774.2008.00051.x     Document Type: Article

References (13)

1. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982 6 : 93 108.
2. Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. A clinical study. Cancer 1995 75 : 2239 43.
3. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997 150 : 177 85.
4. Bancher-Todesca D, Gitsch G, Williams KE et al. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma. Gynecol Oncol 1998 71 : 59 63.
5. Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 1998 29 : 613 19.
6. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000 88 : 814 24.
7. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985 56 : 1452 5.
8. Persson I. The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies. Acta Obstet Gynecol Scand Suppl 1985 130 : 59 66.
9. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992 16 : 600 10.
10. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993 75 : 817 25.
11. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003 13 : 49 58.
12. Nordstrom B, Strang P, Lindgren A, Berstrom R, Tribukait B. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res 1996 16 : 899 904.
13. Lim P, Al Kushi A, Gilks B, Wong F, Aquino-Parsons C. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 2001 91 : 752 7.